Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Diagn Microbiol Infect Dis ; 101(1): 115422, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34111650

ABSTRACT

This study characterized the mechanisms of carbapenem resistance in gram-negative bacteria isolated from patients in Yola, Nigeria. Whole genome sequencing (WGS) was performed on 66 isolates previously identified phenotypically as carbapenem-non-susceptible. The patterns of beta-lactamase resistance genes identified were primarily species-specific. However, blaNDM-7 and blaCMY-4 were detected in all Escherichia coli and most Providencia rettgeri isolates; blaNDM-7 was also detected in 1 Enterobacter cloacae. The E. coli and E. cloacae isolates also shared blaOXA-1, while blaOXA-10 was found in all P. rettgeri, one Pseudomonas aeruginosa and 1 E. coli. Except for Stenotrophomonas maltophilia isolates, which only contained blaL1, most species carried multiple beta-lactamase genes, including those encoding extended-spectrum beta-lactamases, AmpC and OXA in addition to a carbapenemase gene. Carbapenemase genes were either class B or class D beta-lactamases. No carbapenemase gene was detected by WGS in 13.6% of isolates.


Subject(s)
Carbapenems/pharmacology , Genome, Bacterial/genetics , Gram-Negative Bacteria/genetics , beta-Lactam Resistance/genetics , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Gram-Negative Bacteria/classification , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/microbiology , Humans , Microbial Sensitivity Tests , Nigeria , beta-Lactam Resistance/drug effects , beta-Lactamases/genetics
2.
J Clin Microbiol ; 58(12)2020 11 18.
Article in English | MEDLINE | ID: mdl-33115845

ABSTRACT

The growing prevalence and diversity of carbapenemase producers among carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates warrants an expansion of detection capabilities. The purpose of this study was to evaluate the performance of the commercially available Xpert Carba-R (Carba-R) and the research-use-only Xpert Carba-R NxG (Carba-R NxG) in a global collection of P. aeruginosa The challenge set included 123 P. aeruginosa clinical isolates from 12 countries. Isolates were previously categorized via PCR or whole-genome sequencing. Carbapenemase classes tested include VIM, IMP, NDM, SPM, KPC, and GES. Non-carbapenemase (non-CP)-harboring isolates were also tested (negative control). Isolates were tested using the Carba-R NxG and the Carba-R tests per the manufacturer's instructions. Carba-R NxG testing was completed by Cepheid (Sunnyvale, CA), blinded to genotype. Both assays gave negative results for all non-CP isolates and positive results for all VIM, NDM, and KPC isolates. An improvement in IMP detection among isolates was observed (100% detection by Carba-R NxG versus 58% by Carba-R). All SPM and GES isolates, targets not present in commercially available Carba-R, were positive by Carba-R NxG. Two isolates harbored both VIM and GES, while a third isolate contained VIM and NDM. The Carba-R NxG identified both targets in all 3 isolates, while the Carba-R was negative for both GES-containing isolates. Overall, the Carba-R NxG successfully categorized 100% of isolates tested compared with 68% for its predecessor. The Carba-R NxG will expand the detection spectrum of the current Carba-R assay to include SPM, GES, and expanded IMP variants, increasing the global utility of the test.


Subject(s)
Pseudomonas aeruginosa , beta-Lactamases , Bacterial Proteins/genetics , Humans , Pseudomonas aeruginosa/genetics , Sensitivity and Specificity , beta-Lactamases/genetics
3.
J Glob Antimicrob Resist ; 23: 87-93, 2020 12.
Article in English | MEDLINE | ID: mdl-32889141

ABSTRACT

OBJECTIVES: Many multidrug-resistant Gram-negative bacilli (MDR-GNB) harbour multiple ß-lactamases. The aim of this study was to assess the impact of multiple ß-lactamase carriage on the accuracy of susceptibility tests and extended-spectrum ß-lactamase (ESBL) and carbapenemase confirmation methods. METHODS: A total of 50 MDR-GNB, of which 29 carried multiple ß-lactamases, underwent broth microdilution (BMD) and disk diffusion (DD) testing as well as confirmation tests for ESBLs and carbapenemases. Whole-genome sequencing (WGS) was used for ß-lactamase gene identification. RESULTS: Categorical agreement of BMD and DD testing results ranged from 86.5 to 97.7% for 10 ß-lactam agents. BMD and DD algorithms for ESBL detection were highly variable; 6 of 8 positive strains carried an ESBL plus a carbapenemase or an AmpC enzyme, which may confound antimicrobial selection. The sensitivity and specificity of the modified carbapenem inactivation method (mCIM) were both 100%, whilst mCIM and EDTA-modified carbapenem inactivation method (eCIM) when used together to differentiate serine from metallo-ß-lactamase carriage were both 96%. Xpert® Carba-R results (in vitro diagnostic test) were consistent with WGS results. Predicting phenotypic carbapenem resistance from WGS data overall showed 100% specificity but only 66.7% sensitivity for Enterobacterales isolates that were non-susceptible to imipenem and meropenem. CONCLUSIONS: Multiple ß-lactamases in MDR-GNB does not impact DD results, the utility of mCIM/eCIM tests, or Xpert Carba-R results. However, ESBL algorithms produced inconsistent results and predicting carbapenem resistance from WGS data was problematic in such strains.


Subject(s)
Diagnostic Tests, Routine , beta-Lactamases , Bacterial Proteins/genetics , Gram-Negative Bacteria/genetics , beta-Lactamases/genetics
4.
J Glob Antimicrob Resist ; 21: 42-45, 2020 06.
Article in English | MEDLINE | ID: mdl-31472281

ABSTRACT

OBJECTIVES: This study aimed to identify carbapenem-resistant Gram-negative bacteria from clinical specimens of patients in Yola, Nigeria. METHODS: Routine clinical specimens were screened for the presence of carbapenem-resistant Gram-negative bacteria using chromogenic agar plates. Susceptibility of all presumptive isolates to carbapenems was tested by MIC and disk diffusion methods. Real-time PCR was used to test for the presence of carbapenemase genes. RESULTS: Screening of 1741 clinical specimens yielded 119 (6.8%) presumptive carbapenem-resistant Gram-negative bacteria. Antimicrobial susceptibility testing confirmed carbapenem resistance in 105 of these isolates. New Delhi metallo-ß-lactamase (blaNDM) gene was detected in 26 isolates and Verona integron-encoded metallo-ß-lactamase (blaVIM) gene was detected in four. The mechanism of resistance could not be identified in approximately two thirds of the carbapenem-resistant isolates. CONCLUSION: While blaNDM and blaVIM accounted for 28.6% of the resistance seen, further molecular-based studies are needed to characterise the other mechanisms of carbapenem resistance in these isolates.


Subject(s)
Drug Resistance, Bacterial , Gram-Negative Bacteria/classification , Gram-Negative Bacterial Infections/diagnosis , beta-Lactamases/genetics , Bacterial Proteins/genetics , Carbapenems/pharmacology , Female , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/genetics , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/microbiology , Humans , Male , Microbial Sensitivity Tests , Nigeria
SELECTION OF CITATIONS
SEARCH DETAIL
...